DNMT3A and acute myeloid leukemia: In the studies by Jaiswal et al. and Genovese et al. mentioned above, the majority of patients with clonal hematopoiesis harboring mutations in canonical preleukemic mutations (e.g., TET2, ASXL1, or DNMT3A) never developed MDS or AML.